GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome

European Journal of Endocrinology

Volumn 163, Issue 1, 2010, Pages 55-62

  Chiavaroli, Valentina ^a   Liberati, Marco ^a   D'Antonio, Francesco ^a   Masuccio, Fabio ^a   Capanna, Rita ^a   Verrotti, Alberto ^a   Chiarelli, Francesco ^a   Mohn, Angelika ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; GLUCOSE; GONADORELIN DERIVATIVE; INSULIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; TESTOSTERONE; TRIPTORELIN;

ARTICLE; BODY HEIGHT; CHILD; CONTROLLED STUDY; FEMALE; FEMALE INFERTILITY; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; IMMUNOASSAY; INSULIN RESISTANCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; ONSET AGE; OVARY POLYCYSTIC DISEASE; PRECOCIOUS PUBERTY; PREDICTION; PRIORITY JOURNAL; PUBERTY; RISK FACTOR; SCHOOL CHILD; TREATMENT OUTCOME;

BODY HEIGHT; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LONGITUDINAL STUDIES; POLYCYSTIC OVARY SYNDROME; PUBERTY, PRECOCIOUS;

EID: 77954107190     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-1102     Document Type: Article

References (41)

1. Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL & Bougnères PF. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a Randomized Long-Term Pilot Study. Journal of Clinical Endocrinology and Metabolism 1999 84 3575-3578. (Pubitemid 30645208)
2. Orr DP & Ingersoll GM. The contribution of level of cognitive complexity and pubertal timing to behavioral risk in young adolescents. Pediatrics 1995 95 528-533.
3. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, ESPE-LWPES GnRH Analogs Consensus Conference Group, Antoniazzi F, Berenbaum S, Bourguignon JP, Chrousos GP, Coste J, Deal S, de Vries L, Foster C, Heger S, Holland J, Jahnukainen K, Juul A, Kaplowitz P, Lahlou N, Lee MM, Lee P, Merke DP, Neely EK, Oostdijk W, Phillip M, Rosenfield RL, Shulman D, Styne D, Tauber M & Wit JM. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009 123 e752-e762.
4. Kauli R, Korneich L & Laron Z. Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-TRP-6-LHRH. Hormone Research 1990 33 11-17.
5. Escobar ME, Ropelato MG, Ballerini MG, Gryngarten MG, Rudaz MC, Veldhuis JD & Barontini M. Acceleration of luteinizing hormone pulse frequency in adolescent girls with a history of central precocious puberty with versus without hyperandrogenism. Hormone Research 2007 68 278-285. (Pubitemid 350059700)
6. Rosenfield RL. Identifying children at risk of polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 787-796.
7. Palmert MR, Hayden DL, Mansfield MJ, Crigler JF Jr, Crowley WF Jr, Chandler DW & Boepple PA. The longitudinal study of adrenal maturation during gonadal suppression: evidence that adrenarche is a gradual process. Journal of Clinical Endocrinology and Metabolism 2001 86 4536-4542.
8. Heger S, Partsch CJ & Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. Journal of Clinical Endocrinology and Metabolism 1999 84 4583-4590.
9. Rosenfield RL. Does a primary acceleration of LH pulse frequency underlie an association between central precocious puberty and polycystic ovary syndrome? Commentary on Escobar ME et al.: acceleration of LH pulse frequency in adolescent girls with a history of central precocious puberty with versus without hyperandrogenism Hormone Research 2007 68 278-285.
10. Pagàn YL, Srouji SS, Jimenez Y, Emerson A, Gill S & Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. Journal of Clinical Endocrinology and Metabolism 2006 91 1309-1316.
11. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE & Witchel SF. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 4237-4245. (Pubitemid 44833391)
12. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR & Azziz R. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. Journal of Clinical Endocrinology and Metabolism 1998 83 3078-3082. (Pubitemid 28500937)
13. Franks S, McCarthy MI & Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. International Journal of Andrology 2006 29 278-285.
14. Shroff R, Kerchner A, Maifeld M, Van Beek EJ, Jagasia D & Dokras A. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2007 92 4609-4614. (Pubitemid 350223434)
15. Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, Guzick DS & Hoeger KM. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary sindrome. Journal of Clinical Endocrinology and Metabolism 2008 93 4780-4786.
16. Azziz R, Marin C, Hoq L, Badamgarav E & Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. Journal of Clinical Endocrinology and Metabolism 2005 90 4650-4658. (Pubitemid 41159355)
17. Bridges NA, Cooke A, Healy JR, Hindmarsh PC & Brook CGD. Ovaries in sexual precocity. Clinical Endocrinology 1995 42 135-140.
18. Jensen AM, Brocks V, Holm K, Laursen EM & Müller J. Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues. Journal of Pediatrics 1998 132 105-108. (Pubitemid 28082540)
19. Boepple PA. Gonadotropin-releasing hormone agonist therapy of central precocious puberty: growth patterns, final heights and completion of puberty following discontinuation of treatment. In Frontiers in Paediatric Neuroendocrinology, pp 23-29. Eds MO Savage, J-P Bourguignon & AB Grossman, Oxford, London, Edinburgh, Cambridge, Carlton: Blackwell, 1994.
20. Marshall WA & Tanner JM. Variations in pattern of pubertal changes in girls. Archives of Disease in Childhood 1969 44 291-303.
21. Bridges NA, Cooke A, Healy MJ, Hindmarsh PC & Brook CG. Standards for ovarian volume in childhood and puberty. Fertility and Sterility 1993 60 456-460. (Pubitemid 23278801)
22. CDC National Center for Health Statistics, Health E-Stat United States, 2003-2004 NHANES data on the Prevalence of Overweight Among Children and Adolescents.
23. Tanner JM, Goldstein H & Whitehouse RH. Standards for children's height at ages 2-9 years allowing for heights of parents. Archives of Disease in Childhood 1970 45 755-762.
24. Greulich WW & Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. edn 2. Stanford, CA, USA: Stanford University Press, 1959.
25. Bayley N & Pinneau S. Tables for predicting adult height from skeletal age: revised for use with Greulich and Pyle hand standards. Journal of Pediatrics 1952 14 432-441.
26. The Rotterdam ESHRE/ASRM PCOS Consensus Workshop Group. 2003 Revised consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004 19 41-47.
27. DeUgarte CM, Woods KS, Bartolucci AA & Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. Journal of Clinical Endocrinology and Metabolism 2006 91 1345-1350.
28. Ferriman D & Gallwey JD. Clinical assessment of body hair growth in women. Journal of Clinical Endocrinology and Metabolism 1961 21 1440-1447.
29. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES & Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. Journal of Clinical Endocrinology and Metabolism 2004 89 2745-2749. (Pubitemid 38766360)
30. Chang WY, Knochenhauer ES, Bartolucci AA & Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertility and Sterility 2005 83 1717-1723. (Pubitemid 40824804)
31. ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertility and Sterility 2004 81 19-25.
32. Orsini LF, Salardi S, Pilu G, Bovicelli L & Cacciari E. Pelvic organs in premenarcheal girls: real-time ultrasonography. Radiology 1984 153 113-116. (Pubitemid 14046231)
33. Lazar L, Padoa A & Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. Journal of Clinical Endocrinology and Metabolism 2007 92 3483-3489. (Pubitemid 47435324)
34. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G & Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. European Journal of Pediatrics 1998 157 363-367. (Pubitemid 28225436)
35. Lazar L, Kauli R, Pertzelan A & Phillip M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. Journal of Clinical Endocrinology and Metabolism 2002 87 2090-2094. (Pubitemid 34521493)
36. Grumbach MM & Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In Williams Textbook of Endocrinology, edn 9, pp 1509-1625. Eds JD Wilson & DW Forester. Philadelphia: WB Saunders, 1998.
37. Harwood K, Vuguin P & Di Martino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Hormone Research 2007 68 209-217.
38. Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A & Pertzelan A. Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. European Journal of Endocrinology 1995 133 403-406.
39. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, Papaefstathiou A, Lalioti N, Kanaka-Gantenbein C, Piaditis G, Chrousos GP & Dacou-Voutetakis C. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. Journal of Clinical Endocrinology and Metabolism 2010 95 109-117.
40. Barber TM, McCarthy MI, Wass JA & Franks S. Obesity and polycystic ovary syndrome. Clinical Endocrinology 2006 65 137-145.
41. Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP & Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. Journal of Clinical Endocrinology and Metabolism 1998 83 370-373. (Pubitemid 28496508)